Baxter International Inc. (NYSE:BAX), a leading global medtech company, announced that it has signed a definitive agreement to divest its BioPharma Solutions (“BPS”) business to Advent International (“Advent”), one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor. Under the terms of the definitive agreement, Baxter will receive $4.25 billion in cash, subject to certain closing adjustments, with net after-tax proceeds currently estimated to be approximately $3.4 billion. BPS has been a leading provider of sterile contract manufacturing solutions, parenteral delivery systems and customized support services to the pharma and biotech industries for decades.
Read the full article: Baxter Signs Definitive Agreement to Divest Its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25B //
Source: https://www.businesswire.com/news/home/20230508005427/en/Baxter-Signs-Definitive-Agreement-to-Divest-its-BioPharma-Solutions-Business-to-Advent-International-and-Warburg-Pincus-for-4.25-Billion